Unlock the potential of bispecific antibodies (bsAbs) in cancer immunotherapy with this review, featuring no-wash detection platforms. This publication examines how researchers engineered a novel c-MET x CD137 bsAb that achieves tumor-specific immune activation while minimizing off-target effects—a critical advancement in targeted immunotherapy.

Key insights:

• Discover how AlphaLISA™ detection kits provide crucial data on receptor engagement and downstream signaling
• Learn optimization strategies for balancing efficacy with safety in bsAb design
• Explore how monovalent c-MET binding prevents unintended signaling while trivalent CD137 engagement enhances potency

Download this publication review to enhance your immunotherapy research workflow and gain valuable insights into the next generation of targeted cancer treatments.

For research use only. Not for use in diagnostic procedures.